Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 5, 2012, Pages 455-461

  Gupta, Phalguni ^a   Ratner, Deena ^a   Ding, Ming ^a   Patterson, Bruce ^b   Rohan, Lisa C ^c   Reinhart, Todd A ^a   Ayyavoo, Velpandi ^a   Huang, Xioli ^a   Patton, Dorothy L ^d   Ramratnam, Bharat ^e   Cole, Alexander M ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

HIV; microbicide; organ culture; retrocyclin

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; POLYPEPTIDE ANTIBIOTIC AGENT; RC 101; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOHISTOCHEMISTRY; NATURAL KILLER CELL; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY; UTERINE CERVIX MUCOSA; VAGINA DISCHARGE; VIRUS TRANSMISSION;

ADULT; ANTI-INFECTIVE AGENTS; CERVIX UTERI; CYTOKINES; FEMALE; HIV-1; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; ORGAN CULTURE TECHNIQUES; PEPTIDES;

EID: 84864279218     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318258b420     Document Type: Article

References (50)

1. Darroch JE, Frost JJ. Women's interest in vaginal microbicides. Fam Plann Perspect. 1999;31:16-23. (Pubitemid 29072111)
2. Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med. 2006;3:e351.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
4. Baba M, Schols D, Pauwels R, et al. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J Acquir Immune Defic Syndr. 1990;3:493-499. (Pubitemid 20251504)
5. Balzarini J, Naesens L, Verbeken E, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS. 1998;12:1129-1138. (Pubitemid 28302414)
6. Borkow G, Barnard J, Nguyen TM, et al. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol. 1997;71:3023-3030. (Pubitemid 27119946)
7. Ito M, Baba M, Sato A, et al. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 1987;7:361-367. (Pubitemid 17101065)
8. Srinivas RV, Fridland A. Antiviral activities of 9-R-2- phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother. 1998;42:1484-1487. (Pubitemid 28257654)
9. Roth S, Monsour M, Dowland A, et al. Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells. Antimicrob Agents Chemother. 2007;51:1972-1978. (Pubitemid 46903082)
10. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis. 2005;192:1545-1556. (Pubitemid 41504690)
11. Collins KB, Patterson BK, Naus GJ, et al. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med. 2000;6:475-479. (Pubitemid 30208169)
12. Corpa JM, Peris B, Ribes V, et al. Hydrocephalus in a newborn bottlenosed dolphin (Tursiops truncatus). Vet Rec. 2004;155:208-210. (Pubitemid 39193946)
13. Cummins JE, Christensen L, Lennox JL, et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses. 2006;22:788-795. (Pubitemid 44735006)
14. Cummins JE Jr, Guarner J, Flowers L, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother. 2007;51:1770-1779. (Pubitemid 46744157)
15. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS. 2006;20:1237-1245. (Pubitemid 44030371)
16. Greenhead P, Hayes P, Watts PS, et al. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol. 2000;74:5577-5586. (Pubitemid 30346592)
17. Palacio J, Souberbielle BE, Shattock RJ, et al. In vitro HIV1 infection of human cervical tissue. Res Virol. 1994;145:155-161. (Pubitemid 24244513)
18. Zussman A, Lara L, Lara HH, et al. Blocking of cell-free and cellassociated HIV-1 transmission through human cervix organ culture with UC781. AIDS. 2003;17:653-661. (Pubitemid 36521071)
19. Gupta P, Collins KB, Ratner D, et al. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol. 2002;76:9868-9876. (Pubitemid 35006526)
20. Gupta P, Ratner D, Patterson BK, et al. Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res Hum Retroviruses. 2006;22: 419-424. (Pubitemid 43787766)
21. Hira SK, Feldblum PJ, Kamanga J, et al. Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS. 1997;8:243-250. (Pubitemid 27192079)
22. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504-510. (Pubitemid 28384883)
23. van De Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001;26:21-27. (Pubitemid 32115047)
24. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5:e28.
25. Jespers VA, Van Roey JM, Beets GI, et al. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr. 2007; 44:154-158. (Pubitemid 46292217)
26. Rosen RK, Morrow KM, Carballo-Dieguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt). 2008;17:383-392. (Pubitemid 351457833)
27. Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006;325:82-89. (Pubitemid 44573697)
28. Karim QA. Quarraisha Abdool Karim: investigating HIV/AIDS in South Africa. Interview by Priva Shetty. Lancet. 2009;374:871.
29. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med. 2003;198:1551-1562. (Pubitemid 37467169)
30. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005;438:99-102. (Pubitemid 41599827)
31. Ketas TJ, Schader SM, Zurita J, et al. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology. 2007;364:431-440. (Pubitemid 46873705)
32. Cole AM, Hong T, Boo LM, et al. Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci USA. 2002;99:1813-1818. (Pubitemid 34168972)
33. Munk C, Wei G, Yang OO, et al. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses. 2003;19:875-881. (Pubitemid 37338913)
34. Owen SM, Rudolph DL, Wang W, et al. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 2004;20:1157-1165. (Pubitemid 39557866)
35. Sassi AB, Cost MR, Cole AL, et al. Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob Agents Chemother. 2011;55:2282-2289.
36. Chen Y, Rinaldo C, Gupta P. A semiquantitative assay for CD8+ T-cellmediated suppression of human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol. 1997;4:4-10. (Pubitemid 27063693)
37. Majumder B, Venkatachari NJ, O'Leary S, et al. Infection with Vprpositive human immunodeficiency virus type 1 impairs NK cell function indirectly through cytokine dysregulation of infected target cells. J Virol. 2008;82:7189-7200. (Pubitemid 351977736)
38. Huang XL, Fan Z, Borowski L, et al. Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells. Clin Vaccine Immunol. 2009;16:1504-1516.
39. Qin S, Sui Y, Soloff AC, et al. Chemokine and cytokine mediated loss of regulatory T cells in lymph nodes during pathogenic simian immunodeficiency virus infection. J Immunol. 2008;180:5530-5536.
40. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991; 18:176-179.
41. Patton DL, Cosgrove Sweeney YT, Rabe LK, et al. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis. 2002;29:581-587.
42. Roddy RE, Cordero M, Cordero C, et al. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993;4:165-170. (Pubitemid 23161760)
43. Venkataraman N, Cole AL, Ruchala P, et al. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol. 2009;7:e95.
44. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463-472.
45. Patton DL, Sweeney YT, Balkus JE, et al. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother. 2007;51:1608-1615. (Pubitemid 46744134)
46. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993;328:327-335. (Pubitemid 23035333)
47. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses. 1992;8: 191-197.
48. Cole AM, Patton DL, Rohan LC, et al. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One. 2010;5:e15111.
49. Cole AL, Yang OO, Warren AD, et al. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol. 2006;176:6900-6905. (Pubitemid 43787871)
50. Nguyen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides. 2003;24:1647-1654. (Pubitemid 38198072)